Genetic, Microbiological and Behavioral Factors in Obesity (OPTIMIZE-GEN)
OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity.
200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zbigniew Siudak PI, MD, PhD
- 电话号码:+48 41 349 6972
- 邮箱:zbigniew.siudak@ujk.edu.pl
学习地点
-
-
-
Krakow、波兰
- 招聘中
- Waga Zmiany
-
接触:
- Tomasz Witaszek PI, MD
- 电话号码:+48883992287
- 邮箱:kontakt@wagazmiany.pl
-
Warsaw、波兰
- 招聘中
- Luxmed sp zoo
-
接触:
- Justyna Domienik-Karlowicz PI, MD, PhD
- 电话号码:+48 22 450 45 00
- 邮箱:Justyna.Domienik-Karlowicz@luxmed.pl
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients who are overweight or obese and were prescribed tirzepatide for their treatment
描述
Inclusion criteria
- Age 18-65 years
- Consent to participate in the study and providing informed written consent
- Overweight or obese with a BMI >27
Exclusion criteria
- Contraindications to tirzepatide use:
- Type 1 or type 2 diabetes
- Pregnancy or breastfeeding
- Cancer
- Heart failure
- Expected lack of patient compliance
- Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),
- Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis
- Mental illness
- Alcohol dependence syndrome
- Liver cirrhosis
- Post-myocardial infarction or stroke
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
patients with BMI>27
tirzepatide treatment |
GLP1 RA and GIP R polymorphisms will be assesed from venous blood samples stool samples and oral cavity swabs for gut microbiome will be collected to assess V3 and V4 of gene 16s rRNA |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
weight change
大体时间:1 and 6 months
|
weight change measured in kg and as BMI |
1 and 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
treatment discontinuation
大体时间:up to 6 months
|
number of patients who discontinue treatment prematurely |
up to 6 months
|
|
adverse reactions
大体时间:up to 6 months
|
any adverse gastrointestinal events and complications associated with tirzepatide treatment - frequency and intensity |
up to 6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 1/2026 of 6.05.2026
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
We are willing to share data, however, due to the fact that data will come from different clinics and legal entities the form of IPD is to be established.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.